格雷夫茲病治療市場規模、佔有率和成長分析：按治療方法、手術介入、臨床症狀、最終用戶和地區分類－2026年至2033年產業預測

2024 年全球格雷夫茲病治療市場價值為 25 億美元，預計到 2025 年將成長至 26.4 億美元，到 2033 年將成長至 40.5 億美元，在預測期（2026-2033 年）內複合年成長率為 5.5%。

受治療方法的進步以及人們對自體免疫甲狀腺疾病的認知和診斷水平提高的推動，全球格雷夫斯病治療市場正經歷顯著成長。該領域涵蓋多種治療方案，包括抗甲狀腺藥物、放射性碘消融術和創新生物製藥療法，旨在應對甲狀腺功能亢進失控帶來的嚴重後果，例如發病率和視力喪失。近期臨床創新和監管核准的改進正在推動傳統治療方法的革新。治療方法的多樣化和先進診斷技術的普及進一步促進了市場的蓬勃發展。此外，人工智慧在診斷和治療中的應用，透過實現及時介入、改善患者預後和促進個人化護理，尤其是在新興市場，為製藥公司和診斷設備製造商創造了盈利的機會。

全球格雷夫茲病治療市場的成長要素

隨著格雷夫茲病在全球的發病率不斷上升，需要有效治療方法的患者數量也隨之增加，迫使醫療機構更加重視改善診斷和治療策略。患者數量的成長也推動了對現有療法和創新治療方法的需求，刺激了臨床研究的投資和醫療治療方法的擴張。患者的持續需求促使製藥公司改進產品配方和給藥系統，而臨床醫生也正在採用更全面的治療指南。總體而言，發病率的上升正在積極推動市場成長，促使相關人員更多地採用相關產品，並促進長期策略規劃的發展。

全球格雷夫茲病治療市場的限制因素

由於先進治療方法和特殊手術的高昂費用，全球格雷夫茲病治療市場面臨嚴峻挑戰。這些高昂費用限制了病患的就醫途徑，並減少了支付方的報銷支援。出於成本效益的考慮，醫療機構和醫護人員傾向於優先選擇成熟且經濟有效的治療方法，而非更新、潛在更有益的療法。因此，成本敏感性正在影響藥物選擇和籌資策略，阻礙創新治療方法的推廣應用。這種經濟壓力成為治療市場更廣泛接受和發展的重要障礙，最終影響新療法在臨床實踐中的發展和實施。

格雷夫茲病治療市場的全球趨勢

全球格雷夫茲病治療市場正經歷著向個人化醫療模式的顯著轉變。醫療服務提供者擴大根據患者的個別情況量身定做治療方案。這一趨勢強調多學科協作，涉及內分泌科醫生、眼科醫生和心理健康專家，旨在提高治療依從性和整體生活品質。創新通訊協定著重於個人化的給藥策略，促進醫病協作決策，並將病患教育放在第一位。此外，製藥廠商也積極回應，推出標靶治療方案和伴隨診斷產品；同時，與保險公司的磋商也朝著以價值為導向的治療結果方向發展，使治療方法選擇與以患者為中心的長期目標相一致，從而構建一個更加一體化的醫療保健生態系統。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球格雷夫茲病治療市場規模：依治療方法分類

• 抗甲狀腺藥物
• 放射性碘療法
• BETA受體阻斷劑
• 標靶生物製劑

全球格雷夫茲病治療市場規模：依手術介入分類

• 甲狀腺全切除/甲狀腺部分切除術
• 眼眶減壓手術

全球格雷夫茲病治療市場規模：依臨床症狀分類。

• 重點關注甲狀腺功能亢進症
• 格雷夫斯眼病
• 格雷夫斯皮炎

全球格雷夫茲病治療市場規模：依最終用戶分類

• 內分泌專科診所
• 醫院及三級醫療機構
• 零售藥房

全球格雷夫茲病治療市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要企業2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要企業完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要企業簡介

• Genzyme Corporation
• AbbVie Inc.
• Merck & Co., Inc.
• Eli Lilly and Company
• Amgen Inc.
• Novo Nordisk A/S
• Pfizer Inc.
• Bristol-Myers Squibb Company
• Sanofi
• GlaxoSmithKline plc
• AstraZeneca
• Johnson & Johnson
• Bayer AG
• Takeda Pharmaceutical Company Limited
• Medtronic plc
• Boehringer Ingelheim
• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• Astellas Pharma Inc.
• Ipsen SA

結論與建議

Global Graves Disease Treatment Market size was valued at USD 2.5 Billion in 2024 and is poised to grow from USD 2.64 Billion in 2025 to USD 4.05 Billion by 2033, growing at a CAGR of 5.5% during the forecast period (2026-2033).

The global Graves disease treatment market is experiencing significant growth driven by increased awareness and the diagnosis of autoimmune thyroid disorders, alongside advancements in therapy. This sector includes a range of treatment options, such as antithyroid medications, radioactive iodine ablation, and innovative biologic therapies, addressing the severe consequences of uncontrolled hyperthyroidism, including morbidity and vision loss. Historical treatment methods are evolving due to recent clinical innovations and regulatory approvals that enhance care pathways. The market is further stimulated by therapeutic diversification and heightened accessibility to advanced diagnostic technologies. Additionally, AI integration in diagnosis and treatment facilitates timely interventions, improves patient outcomes, and allows for greater customization of care, particularly in emerging markets, creating lucrative opportunities for pharmaceutical and diagnostic companies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Graves Disease Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Graves Disease Treatment Market Segments Analysis

Global graves disease treatment market is segmented by therapy type, surgical intervention, clinical manifestation, end-user and region. Based on therapy type, the market is segmented into Antithyroid Drugs, Radioactive Iodine Therapy, Beta-Blockers and Targeted Biologics. Based on surgical intervention, the market is segmented into Total/Partial Thyroidectomy and Orbital Decompression. Based on clinical manifestation, the market is segmented into Hyperthyroidism Focus, Graves' Ophthalmopathy and Graves' Dermopathy. Based on end-user, the market is segmented into Endocrine Specialty Clinics, Hospitals & Tertiary Care Centers and Retail Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Graves Disease Treatment Market

The rising global incidence of Graves disease has led to a growing number of patients in need of effective treatment solutions, compelling healthcare providers to focus on improved diagnostic and management strategies. As the patient population expands, so does the demand for both established and innovative therapies, which in turn drives investment in clinical research and the enhancement of healthcare infrastructure. This persistent need from patients encourages pharmaceutical companies to refine their product formulations and delivery systems, while clinicians adopt more comprehensive treatment guidelines. Overall, the increased prevalence actively propels market growth, facilitating consistent product utilization and long-term strategic planning among industry stakeholders.

Restraints in the Global Graves Disease Treatment Market

The Global Graves Disease Treatment market faces significant challenges due to high costs linked to advanced therapies and specialized procedures, which can restrict patient access and reduce reimbursement support from payers. These affordability concerns prompt healthcare providers and institutions to favor established, cost-effective treatments over newer, potentially more beneficial options. Consequently, cost sensitivity affects formulary choices and procurement strategies, hindering the adoption of innovative treatments. This economic pressure serves as a notable barrier to the wider acceptance and growth of the treatment market, ultimately impacting the development and integration of new therapeutic solutions in clinical practice.

Market Trends of the Global Graves Disease Treatment Market

The Global Graves Disease Treatment market is witnessing a notable shift towards personalized care models, where healthcare providers are increasingly customizing treatment plans to fit individual patient profiles. This trend emphasizes a multidisciplinary approach, engaging endocrinologists, ophthalmologists, and mental health specialists to enhance treatment adherence and overall quality of life. Innovative protocols are focusing on individualized dosing strategies, fostering shared decision-making, and prioritizing patient education. Additionally, manufacturers are responding with targeted therapeutic options and companion diagnostics, while payer conversations are steering towards value-based outcomes that align therapy selection with long-term patient-centered goals, creating a more integrated healthcare ecosystem.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Graves Disease Treatment Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• Antithyroid Drugs
• Radioactive Iodine Therapy
• Beta-Blockers
• Targeted Biologics

Global Graves Disease Treatment Market Size by Surgical Intervention & CAGR (2026-2033)

• Market Overview
• Total/Partial Thyroidectomy
• Orbital Decompression

Global Graves Disease Treatment Market Size by Clinical Manifestation & CAGR (2026-2033)

• Market Overview
• Hyperthyroidism Focus
• Graves' Ophthalmopathy
• Graves' Dermopathy

Global Graves Disease Treatment Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Endocrine Specialty Clinics
• Hospitals & Tertiary Care Centers
• Retail Pharmacies

Global Graves Disease Treatment Market Size & CAGR (2026-2033)

• North America (Therapy Type, Surgical Intervention, Clinical Manifestation, End-User)
  • US
  • Canada
• Europe (Therapy Type, Surgical Intervention, Clinical Manifestation, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Surgical Intervention, Clinical Manifestation, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Surgical Intervention, Clinical Manifestation, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Surgical Intervention, Clinical Manifestation, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Genzyme Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations